BioSpace News Archive

Samsung Biologics, the world’s leading contract development and manufacturing organization, published its second annual ESG Report, reflecting the company’s sustainability efforts in 2021 to address a wide range of environmental, social, and governance activities related to its business.

KAHR , a clinical-stage cancer immunotherapy company developing novel bi-functional fusion proteins, today announced the appointment of Jennifer Minai-Azary to its Board of Directors. The appointment is effective immediately.

Biomica Ltd. today announced the successful enrollment of the first patient in its first Proof-of-Concept (POC) Phase I clinical trial.

EyePoint Pharmaceuticals, Inc. today announced it will host an Investor Day that will be held on Monday, July 18, 2022 from 8:00 a.m. to 11:00 a.m. ET.

Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that the US Food & Drug Administration (“FDA”) has granted Breakthrough Device designation for the Company’s Toraymyxin™ (“PMX”) device, a therapeutic hemoperfusion device that removes endotoxin, which can cause septic shock.

Lipocine Inc announced today that the U.S. Food and Drug Administration (“FDA”) has accepted the company’s Investigational New Drug Application (“IND”) for its neuroactive steroid (“NAS”) candidate, LPCN 2101, as a potential treatment for adults with epilepsy.

Seqirus, a global leader in influenza prevention and a business of CSL Limited, announced that it has begun to ship its portfolio of innovative cell-based, adjuvanted and egg-based seasonal influenza vaccines across the U.S. in preparation for the 2022/23 influenza season.

Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule therapeutics, announced that it has raised $50 million in a Series D financing round, co-led by new investors Sands Capital and Vivo Capital, with additional participation from new investor Dreavent 6.

Thoughtworks (NASDAQ: TWKS), a global technology consultancy that integrates strategy, design and engineering to drive digital innovation, today announced the signing of a multi-year agreement with PCI Pharma Services, a leading global contract development and manufacturing organization (CDMO).

ENDRA Life Sciences Awarded Two Additional Chinese Patents for its TAEUS ® System.